Adrian spoke with us about how his life has changed since advocating for changing his treatment to COAGADEX—the first and only treatment specifically for hereditary factor X deficiency.
Growing up in Mexico, Adrian made frequent visits to the emergency room with bleeding, painful bruises, and joint swelling. After moving to the United States in his mid-20s, Adrian worked construction. While he tried to be careful, Adrian continued to have serious bleeds and made many trips to the emergency room. It was only after being hospitalized for a brain bleed from a construction accident that he was finally diagnosed with factor X deficiency.
After more than 25 years of bruising and pain, Adrian was finally treated with fresh frozen plasma (FFP) for the first time. While he continued to work construction, he also still experienced bruising, swelling, and pain. He also made frequent trips to the emergency room. While FFP did help stop his bleeding, it also made him feel tired and weak on the days of his treatment. Adrian said, “My wife needed to run all the errands and attend all social activities without me.”
Tired of missing work and family activities, Adrian became his own advocate. His sister, who also had factor X deficiency, told him about a product called COAGADEX that she had recently started taking. Working with a patient advocate, his doctor and insurance provider, Adrian switched to COAGADEX in November 2016. With COAGADEX, he is able to infuse his treatment and then get back to many of the activities he enjoys.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.
Contraindication for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.